Odds of COVID-19 Mortality Lower for Women Receiving HRT

MONDAY, May 23, 2022 (HealthDay News) -- Hormone replacement therapy (HRT) use is associated with reduced odds of all-cause mortality among women with a recorded diagnosis of COVID-19, according to a study published online May 17 in Family Practice.
Hajira Dambha-Miller, M.R.C.G.P., Ph.D., from the University of Southampton in the United Kingdom, and colleagues conducted a retrospective cohort study to examine the association between HRT or combined oral contraceptive pill (COCP) use and the likelihood of death among women with COVID-19. A cohort of 1,863,478 women older than 18 years of age from 465 general practices in England was identified.
The researchers identified 5,451 COVID-19 cases within the cohort. During the follow-up period (mean, 164.9 days), 12.2 percent of women died. HRT was associated with a reduction in all-cause mortality in COVID-19 (adjusted odds ratio, 0.22). In women prescribed COCPs, there were no reported events for all-cause mortality, preventing further examination of the impact of COCPs.
"We found that HRT prescription within six months of a recorded diagnosis of COVID-19 infection was associated with a reduction in all-cause mortality," the authors write. "From these results, women should be reassured that there is no indication to discontinue HRT use because of the pandemic."
Related Posts
Worries May Raise Men’s Heart Risks, Even When Young
MONDAY, Jan. 24, 2022 (HealthDay News) -- Worrying can take a toll on your...
Los casos de COVID se disparan de nuevo en los hogares de ancianos de EE. UU.
LUNES, 17 de enero de 2022 (HealthDay News) -- Los residentes de los hogares de...
Lung Cancer Survival Continues to Improve, But Not for All
TUESDAY, Nov. 16, 2021 (HealthDay News) -- Lung cancer survival rates in the...
Insurance Type, Maternal Race Impact Odds of Reporting to CPS
MONDAY, July 18, 2022 (HealthDay News) -- For children hospitalized with...